Bortezomib and vorinostat in refractory acute myelogenous leukemia and high-risk myelodysplastic syndromes: produces stable disease but at the cost of high toxicity

被引：0
|
作者：
E D Warlick
Q Cao
J Miller
机构：
[1] Oncology,Division of Hematology
[2] and Transplantation,undefined
[3] University of Minnesota Medical School,undefined
[4] Biostatistics and Informatics,undefined
[5] Masonic Cancer Center,undefined
[6] University of Minnesota,undefined
来源：
Leukemia | 2013年 / 27卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1789 / 1791
页数：2
相关论文
共 50 条
  • [1] Bortezomib and vorinostat in refractory acute myelogenous leukemia and high-risk myelodysplastic syndromes: produces stable disease but at the cost of high toxicity
    Warlick, E. D.
    Cao, Q.
    Miller, J.
    LEUKEMIA, 2013, 27 (08) : 1789 - 1791
  • [2] Pilot study of low dose melphalan and bortezomib for treatment of acute myelogenous leukemia and high-risk myelodysplastic syndromes.
    Bubis, JA
    Ely, P
    Meehan, KR
    Stearns, D
    Schaal, AD
    Kimtis, EA
    Lowrey, C
    Bengtson, EM
    Hill, J
    Gautier, M
    BLOOD, 2005, 106 (11) : 237B - 237B
  • [3] Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome
    Lee, ST
    Jang, JH
    Suh, HC
    Hahn, JS
    Ko, YW
    Min, YH
    AMERICAN JOURNAL OF HEMATOLOGY, 2001, 68 (04) : 237 - 245
  • [4] Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes
    Tsimberidou, A
    Estey, E
    Cortes, J
    Thomas, D
    Faderl, S
    Verstovsek, S
    Garcia-Manero, G
    Keating, M
    Albitar, M
    O'Brien, S
    Kantarjian, H
    Giles, F
    CANCER, 2003, 97 (06) : 1481 - 1487
  • [5] Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome
    Borthakur, Gautam
    Estrov, Zeev
    Garcia-Manero, Guillermo
    Williams, Betsy
    Wathen, Jay K.
    Konopleva, Marina
    Burger, Jan
    Ferrajoli, Alessandra
    George, Solly
    Kantarjian, Hagop
    BLOOD, 2008, 112 (11) : 1026 - 1026
  • [6] Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome
    Daver, Naval
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Estrov, Zeev
    Konopleva, Marina
    Burger, Jan A.
    O'Brien, Susan
    Ferrajoli, Alessandra
    Verstovsek, Srdan
    Kadia, Tapan M.
    Jabbour, Elias J.
    Faderl, Stefan
    Diaz-Pines-Mateo, Maria
    Pemmaraju, Naveen
    Pierce, Sherry A.
    Cortes, Jorge E.
    Borthakur, Gautam
    BLOOD, 2012, 120 (21)
  • [7] Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
    Lee, ST
    Hahn, JS
    Ko, YW
    Min, YH
    BLOOD, 2001, 98 (11) : 215B - 215B
  • [8] Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes
    Borthakur, Gautam
    Huang, Xuelin
    Kantarjian, Hagop
    Faderl, Stefan
    Ravandi, Farhad
    Ferrajoli, Alessandra
    Torma, Ritva
    Morris, Gail
    Berry, Donald
    Issa, Jean-Pierre
    LEUKEMIA & LYMPHOMA, 2010, 51 (01) : 73 - 78
  • [9] Predictors and Outcome of Acute Kidney Injury in Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplastic Syndrome
    Lahoti, Amit
    Kantarjian, Hagop
    Salahudeen, Abdulla K.
    Ravandi, Farhad
    Cortes, Jorge E.
    Faderl, Stefan
    O'Brien, Susan
    Wierda, William
    Mattiuzzi, Gloria N.
    CANCER, 2010, 116 (17) : 4063 - 4068
  • [10] CD30 Expression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes
    Zheng, Wenli
    Medeiros, L. Jeffrey
    Hu, Ying
    Powers, Linda
    Cortes, Jorge E.
    Ravandi-Kashani, Farhad
    Kantarjian, Hagop H.
    Wang, Sa A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (03): : 307 - 314
12345